Prolia (Denosumab) Cost in Utah 2026

What Is Prolia (Denosumab) and Why Does Cost Matter?

Prolia is a fully human monoclonal antibody that inhibits RANK ligand, slowing osteoclast-driven bone breakdown. The FDA approved it in 2010 for postmenopausal women with osteoporosis at high fracture risk, and subsequent label expansions cover men with osteoporosis, patients on long-term glucocorticoids, and patients with bone loss from aromatase inhibitor or androgen-deprivation therapy. [1][2]

Because the injection is administered only twice a year, patients and clinicians sometimes underestimate the annualized cost. At Amgen's 2026 wholesale acquisition price, two doses cost roughly $3,000 per year before any discounts, copay assistance, or insurance adjustment. For a Utah patient paying entirely out of pocket, that number can be a barrier to treatment adherence, and missed or delayed doses carry a real clinical penalty: the FREEDOM extension trial demonstrated rapid bone mineral density loss and a potential rebound increase in vertebral fracture risk when denosumab is discontinued without transitioning to an antiresorptive agent. [3]

Understanding every pricing pathway available in Utah, from Medicaid to 503A compounding to the Amgen savings card, helps patients and prescribers make the right choice before the first injection is ordered.

2026 Prolia Cash Price in Utah Retail Pharmacies

The cash price for a single 60 mg/mL prefilled syringe of Prolia at major Utah retail chains (Walmart, Smith's, Harmons, CVS, Walgreens) sits at approximately $1,500 per dose in 2026, consistent with Amgen's national list price.

That figure is the starting point for negotiation, not a fixed ceiling. GoodRx and similar discount platforms have occasionally listed denosumab at $1,100 to $1,300 per dose at specific Utah zip codes depending on the pharmacy's contracted rate with each discount aggregator. Prices shift monthly, so checking GoodRx or NeedyMeds directly before each fill is worth doing.

The FDA approved the first biosimilar denosumab, Jubbonti (denosumab-bbdz, Sandoz) and Wyost, in 2024, with commercial availability beginning in mid-2025. [4] As biosimilar market penetration increases through 2026, retail prices at some Utah pharmacies may begin to decrease, though the trajectory is not yet fully established.

Two doses per year at $1,500 each equals $3,000 annually, or roughly $250 per month when amortized. That comparison matters when patients are weighing denosumab against oral bisphosphonates, which can cost under $15 per month as generic alendronate.

Utah Medicaid Coverage for Prolia (Denosumab) in 2026

Utah Medicaid does not cover Prolia (denosumab) for osteoporosis as of the 2026 formulary. This is one of the most searched questions among Utah patients, and the answer is clear: standard fee-for-service Utah Medicaid and the Healthy Utah (Medicaid expansion) managed care formularies exclude branded Prolia for the osteoporosis indication.

Patients enrolled in Utah Medicaid who have a documented osteoporosis diagnosis should ask their prescriber about covered alternatives. Generic alendronate (70 mg weekly) and risedronate are typically covered under Utah Medicaid with minimal cost-sharing. For patients who have already failed or are contraindicated to oral bisphosphonates, a prescriber may submit a prior authorization or exception request to a managed care organization arguing medical necessity, but approval rates for this pathway are low and approval is not guaranteed.

Patients with Medicaid-covered cancer diagnoses may find separate coverage pathways for denosumab when prescribed for prevention of skeletal-related events using the 120 mg monthly Xgeva formulation, which is a distinct drug with a different indication from Prolia. However, Xgeva is not interchangeable with Prolia for osteoporosis.

If you are a dual-eligible (Medicare and Medicaid) Utah resident, see the Medicare Part B section below, which applies different rules.

Medicare Part B Coverage of Prolia in Utah

Medicare Part B covers Prolia when it is administered in a physician's office or outpatient hospital setting, which is the standard delivery model for a subcutaneous injection given twice yearly. Under Part B, denosumab is reimbursed at the Average Sales Price plus 6 percent, with the patient responsible for a 20 percent coinsurance after the Part B deductible ($257 in 2025, subject to annual adjustment). [5]

For a Part B-covered patient with a Medigap supplement plan, that 20 percent coinsurance may be fully absorbed by the supplemental policy. Without a supplement, the patient's share of one $1,500 dose is approximately $300, or $600 per year.

Utah Medicare Advantage plans administer their own formularies. Some Utah Advantage plans cover Prolia under a medical benefit with a specialty tier copay ranging from $100 to $350 per injection per plan documents reviewed in prior contract years. Patients should pull their plan's Evidence of Coverage document and search for "denosumab" or "Prolia" under the Part B drug benefit section.

Commercial Insurance and Prior Authorization in Utah

Most major commercial insurers operating in Utah, including SelectHealth, PEHP (Public Employees Health Program), Regence BlueCross BlueShield of Utah, and UnitedHealthcare, cover Prolia under a specialty tier, usually Tier 4 or Tier 5. Prior authorization is almost universally required.

Typical prior authorization criteria across Utah commercial plans in 2026 include:

• Confirmed osteoporosis diagnosis with a DEXA T-score of -2.5 or lower, or documented low-trauma fracture.
• Evidence of an inadequate response to or contraindication to a generic oral bisphosphonate (usually defined as 12 months of alendronate or risedronate therapy without T-score improvement, or a documented upper GI contraindication).
• Prescriber attestation of high fracture risk.

The 2020 American Association of Clinical Endocrinology (AACE) osteoporosis guidelines state that denosumab is appropriate as a first-line agent for patients with severe osteoporosis (T-score at or below -2.5 with fracture history) or in patients who cannot tolerate oral bisphosphonates. [6] Citing that guideline directly in a prior authorization request strengthens the clinical argument.

After prior authorization is approved, specialty tier cost-sharing for commercially insured Utah patients typically falls between $100 and $350 per dose before copay assistance.

Amgen Prolia SupportPlus Savings Card in Utah

Amgen's Prolia SupportPlus program is available to commercially insured Utah patients who are not using a government-funded insurance program. Eligible patients may pay as little as $0 per dose, with Amgen covering up to a defined out-of-pocket maximum per calendar year.

Key eligibility rules as of 2026:

1. Patient must have commercial (private) insurance, either employer-sponsored or individual marketplace.
2. Medicare, Medicaid, and CHIP enrollees are not eligible.
3. The drug must be covered by the patient's commercial plan (even at a high copay tier).
4. The prescribing provider must enroll through the Amgen SupportPlus portal.

Enrollment takes five to ten minutes online and does not require income verification. Once enrolled, the savings card is applied at the point of injection, reducing or eliminating the patient's cost-sharing. The card is renewed annually.

For Utah patients whose commercial plan has approved a prior authorization and who enroll in SupportPlus, the real out-of-pocket cost of Prolia may be zero per dose. That makes the drug effectively free for this subset of patients, at least while commercial coverage and the copay assistance program remain active. Patients who retire and move to Medicare will lose SupportPlus eligibility.

Compounded Denosumab in Utah: 503A Pharmacies and Legal Status

Compounded denosumab is legally available through licensed 503A pharmacies in Utah for patients with a valid prescription from a licensed Utah prescriber. [7]

This point generates significant confusion nationally. Here is what "503A" means: the FDA exempts compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act from standard new drug approval requirements when they compound for individually identified patients based on a valid prescription. Utah state law permits 503A operations, and the Utah Division of Occupational and Professional Licensing (DOPL) licenses these facilities.

Denosumab is a large-molecule biologic. Compounding a biologic differs from compounding a small-molecule drug, and the FDA has raised concerns about the biological equivalence and sterility of compounded biologics broadly. Prescribers considering this route should document their clinical rationale and confirm that the 503A pharmacy they are recommending holds current Utah licensure and passes third-party sterility testing.

The table below outlines a practical decision framework for Utah prescribers choosing between branded Prolia, biosimilar denosumab, and compounded denosumab:

HealthRX Utah Denosumab Prescribing Cost Framework (2026)

| Patient Scenario | Recommended Pathway | Estimated Annual Cost | |---|---|---| | Commercial insurance, PA approved | Branded Prolia + SupportPlus card | $0 to $700 | | Medicare Part B, with Medigap | Branded Prolia, billed Part B | $0 to $120 | | Medicare Part B, no supplement | Branded Prolia, billed Part B | ~$600 | | Utah Medicaid only | Generic bisphosphonate first; PA exception for denosumab if contraindicated | $0 (bisphosphonate) | | Uninsured, cannot afford branded | Licensed 503A compounded denosumab with prescriber oversight | Varies; may be substantially lower | | Uninsured, moderate income | Amgen Prolia Patient Assistance Program (income-based) | $0 if approved |

Telehealth Prescribing of Prolia in Utah

A Utah prescriber can legally prescribe Prolia via telehealth. Utah's telehealth laws, updated under HB 224 (2020) and aligned with post-COVID interstate practice rules, allow licensed Utah physicians, nurse practitioners, and physician assistants to evaluate and prescribe via synchronous video or telephone for established clinical indications, including osteoporosis. [8]

The practical sequence for a Utah telehealth Prolia prescription is:

1. Telehealth visit with a licensed Utah provider who reviews the patient's DEXA scan results, fracture history, and prior medication records.
2. Prescriber confirms diagnosis, fracture risk, and prior bisphosphonate history for insurance or PA purposes.
3. Electronic prescription sent to a Utah pharmacy or to the provider's in-office supply for administration.
4. Patient receives injection at a local infusion center, primary care office, or rheumatology practice, since Prolia is a subcutaneous injection that requires clinical administration and monitoring.

Telehealth prescribing does not change the administration requirement. Patients cannot self-administer Prolia at home under standard clinical protocol, because hypocalcemia monitoring and proper injection technique require clinical oversight, particularly for the first dose.

Clinical Efficacy: Why Prolia Is Worth Its Cost for High-Risk Patients

The cost-access discussion above does not mean much without clinical context.

In the FREEDOM trial (N=7,808 to 36 months), subcutaneous denosumab 60 mg every 6 months reduced new vertebral fractures by 68 percent versus placebo (7.2% placebo vs. 2.3% denosumab, P<0.001) and reduced hip fractures by 40 percent (1.2% vs. 0.7%, P<0.05). [9] The FREEDOM extension followed patients for up to 10 years and showed continued fracture reduction with sustained therapy. [3]

The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline states: "For patients at high or very high risk of fracture, we recommend treatment with a pharmacological agent. Denosumab is among the first-line options for such patients." [10]

For a 68-year-old Utah woman with a documented hip T-score of -2.8 and one prior vertebral fracture, the clinical case for denosumab is strong regardless of cost. For a 62-year-old with a T-score of -2.0 and no fracture history, an oral generic bisphosphonate at $15 per month may be the appropriate first step.

Prolia Discontinuation Risk: A Cost Factor Often Overlooked

One cost-related consideration that competitor articles routinely miss is the discontinuation risk.

When denosumab is stopped without transitioning to an antiresorptive agent, bone mineral density falls rapidly, and rebound vertebral fractures have been documented within 7 to 24 months of the last dose. A 2017 analysis published in the Journal of Bone and Mineral Research found that 15 of 26 patients who discontinued denosumab without subsequent antiresorptive therapy experienced multiple new vertebral fractures. [11]

This means denosumab is not a drug you start without a long-term plan. Before initiating therapy, prescribers and patients in Utah should confirm that the chosen payment pathway (insurance, copay card, compounding, or patient assistance) can be sustained for at least two to five years, or that a clear transition plan to zoledronate or alendronate exists before denosumab is stopped.

A single missed dose or a lapse in insurance coverage can have serious clinical consequences. Patients using the Amgen SupportPlus card should be counseled to re-enroll at the start of each calendar year, not just before their next injection.

Amgen Patient Assistance Program for Uninsured Utah Patients

Patients who are uninsured and cannot afford Prolia may qualify for Amgen's Safety Net Foundation program, which provides Prolia at no cost to eligible low-income patients. Income thresholds and documentation requirements vary by year. As of 2025, the program served patients with household incomes up to 500 percent of the federal poverty level in some categories.

Utah patients should apply through the Amgen Assist 360 program (available at amgensupportplus.com) or ask their prescriber's office to submit on their behalf. Processing typically takes two to four weeks. Bridge doses are sometimes available while the application is reviewed, but availability depends on the clinic's relationship with Amgen.

Comparing Denosumab to Alternatives on Cost and Efficacy in Utah

For Utah patients and prescribers weighing denosumab against other agents, a brief comparison is useful.

Generic alendronate 70 mg weekly costs $10 to $20 per month at Utah pharmacies and reduces vertebral fractures by roughly 47 percent versus placebo in the FIT trial (N=2,027). [12] It is covered by Utah Medicaid. Its main limitations are upper GI intolerance and an inconvenient dosing protocol (fasting, upright position for 30 minutes).

Zoledronic acid (Reclast) 5 mg IV annually costs $250 to $600 per infusion at Utah outpatient infusion centers and is covered by Medicare Part B. The HORIZON Key Fracture Trial (N=7,765) showed a 70 percent reduction in vertebral fractures at 36 months. [13] For patients who cannot tolerate oral bisphosphonates, this is often the most cost-effective Medicare-covered alternative to denosumab.

Teriparatide (Forteo) and romosozumab (Evenity) are anabolic agents used for very high fracture risk; both cost more than denosumab and carry distinct safety profiles. They are outside the scope of this article.

Practical Steps for Utah Patients Starting Prolia in 2026

Getting the cost right before the first injection requires a specific sequence. Here is the recommended order of operations:

1. Get a DEXA scan. Most Utah commercial insurers cover DEXA every two years for women 65 and older, or earlier with risk factors. DEXA results directly determine whether prior authorization criteria are met.
2. Confirm your insurance status and formulary. Pull your plan's drug list and look up denosumab under both the medical benefit (Part B or office visit) and the pharmacy benefit.
3. Ask your prescriber to submit prior authorization before any prescription is written. PA approval time averages five to ten business days at most Utah plans.
4. Enroll in Amgen SupportPlus immediately after PA approval if you have commercial insurance.
5. If uninsured or on Medicaid, ask your prescriber about licensed 503A compounding pharmacies or the Amgen Safety Net Foundation.
6. Confirm the administration site. Most Utah primary care offices, rheumatology practices, and some OBGYN offices administer Prolia in-office under a buy-and-bill model. Confirm they have stock before your appointment.
7. Schedule your follow-up dose exactly 6 months from the first injection. A gap longer than 7 months begins to erode fracture protection.

Calcium (1,000 to 1 to 200 mg daily from diet and supplement combined) and vitamin D (at least 400 IU daily, with most guidelines recommending 800 to 1 to 000 IU) must be adequate before the first dose to reduce hypocalcemia risk. [2]